Literature DB >> 18640684

Expression of transforming growth factor-beta1, -beta2 and -beta3 in normal and diseased canine mitral valves.

H Aupperle1, I März, J Thielebein, H-A Schoon.   

Abstract

The pathogenesis of chronic valvular disease (CVD) in dogs remains unclear, but activation and proliferation of valvular stromal cells (VSC) and their transdifferentiation into myofibroblast-like cells has been described. These alterations may be influenced by transforming growth factor-beta (TGF-beta), a cytokine involved in extracellular matrix (ECM) regulation and mesenchymal cell differentiation. The present study investigates immunohistochemically the expression of TGF-beta1, -beta2, -beta3 and smooth muscle alpha actin (alpha-SMA) in normal canine mitral valves (MVs) (n=10) and in the valves of dogs with mild (n=7), moderate (n=14) and severe (n=9) CVD. In normal mitral valves there was no expression of alpha-SMA but VSC displayed variable expression of TGF-beta1 (10% of VSC labelled), TGF-beta2 (1-5% labelled) and TGF-beta3 (50% labelled). In mild CVD the affected atrialis contain activated and proliferating alpha-SMA-positive VSC, which strongly expressed TGF-beta1 and -beta3, but only 10% of these cells expressed TGF-beta2. In unaffected areas of the leaflet there was selective increase in expression of TGF-beta1 and -beta3. In advanced CVD the activated subendothelial VSC strongly expressed alpha-SMA, TGF-beta1 and -beta3. Inactive VSC within the centre of the nodules had much less labelling for TGF-beta1 and -beta3. TGF-beta1 labelling was strong within the ECM. These data suggest that TGF-beta plays a role in the pathogenesis of CVD by inducing myofibroblast-like differentiation of VSC and ECM secretion. Changed haemodynamic forces and expression of matrix metalloproteinases (MMPs) may in turn regulate TGF-beta expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640684     DOI: 10.1016/j.jcpa.2008.05.007

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  11 in total

Review 1.  Differentiating the aging of the mitral valve from human and canine myxomatous degeneration.

Authors:  Patrick S Connell; Richard I Han; K Jane Grande-Allen
Journal:  J Vet Cardiol       Date:  2012-02-24       Impact factor: 1.701

Review 2.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

3.  Generation of mice with a conditional allele for the transforming growth factor beta3 gene.

Authors:  Thomas Doetschman; Teodora Georgieva; Hongqi Li; Thomas D Reed; Christina Grisham; Jacqueline Friel; Mark A Estabrook; Connie Gard; L P Sanford; Mohamad Azhar
Journal:  Genesis       Date:  2012-01-06       Impact factor: 2.487

4.  TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves.

Authors:  Michael A Hagler; Thomas M Hadley; Heyu Zhang; Kashish Mehra; Carolyn M Roos; Hartzell V Schaff; Rakesh M Suri; Jordan D Miller
Journal:  Cardiovasc Res       Date:  2013-04-03       Impact factor: 10.787

5.  Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model.

Authors:  Susanna Cirera; Sophia G Moesgaard; Nora E Zois; Nathja Ravn; Jens P Goetze; Signe E Cremer; Tom Teerlink; Páll S Leifsson; Jesper L Honge; J Michael Hasenkam; Lisbeth H Olsen
Journal:  Endocr Connect       Date:  2013-09-24       Impact factor: 3.335

6.  The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failure.

Authors:  Magdalena Hulanicka; Magdalena Garncarz; Marta Parzeniecka-Jaworska; Michał Jank
Journal:  BMC Genomics       Date:  2014-06-21       Impact factor: 3.969

7.  Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model.

Authors:  Vicky K Yang; Kerry A Loughran; Dawn M Meola; Christine M Juhr; Kristen E Thane; Airiel M Davis; Andrew M Hoffman
Journal:  J Extracell Vesicles       Date:  2017-07-12

8.  Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.

Authors:  Karen Tan; Greg Markby; Rhona Muirhead; Rachel Blake; Lisa Bergeron; Greg Fici; Kim Summers; Vicky Macrae; Brendan Corcoran
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

Review 9.  Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human.

Authors:  Greg R Markby; Kim M Summers; Vicky E MacRae; Brendan M Corcoran
Journal:  Vet Sci       Date:  2017-07-17

10.  Comparative transcriptomic profiling of myxomatous mitral valve disease in the cavalier King Charles spaniel.

Authors:  G R Markby; V E Macrae; B M Corcoran; K M Summers
Journal:  BMC Vet Res       Date:  2020-09-23       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.